Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #706 | April 7, 2017  

Attention Washington D.C. Residents

The American Thoracic Society's Public Advisory Roundtable is holding a Meet the Experts Day in our nation's capital on May 20.  The foundation's Director of Programs and Services Kerri A. Connolly is set to deliver par logo.pngopening remarks.  A great lineup of speakers, appearing at the behest of the committee, is on tap.  Click here for more.

Clinical Trial Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that the Company will be proceeding with a single Phase 3 study to support a New Drug Application ("NDA") for anabasum for the treatment of diffuse cutaneous systemic sclerosis ("systemic sclerosis").  Click here for more.

More About Juvenile Scleroderma

Here is an article with some great insight and information on the nuances of localized juvenile scleroderma.  The authors pored through a great deal of data to present the most accurate and updated information. Be sure to check it out here!juvenile scleroderma 3.jpg


Learn How to Knockout Dreaded Seasonal Allergies

Seasonal allergies, also called hay fever or allergic rhinitis, are triggered each spring, summer, and fall when trees, weeds, and grasses release seasonal allergy.jpgpollen into the air. When the pollen ends up in your nose and throat, it can bring on sneezing, runny nose, coughing, and itchy eyes and throat. People manage seasonal allergies by taking medication, avoiding exposure to the substances that trigger their allergic reactions, or having a series of “allergy shots” (a form of immunotherapy).  Here's more.

Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Make a gift
2016 Instagram

 Actelion Logo
Bayer logo
reata small




Sencis Ad - eLetter

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.